Incretin Action in Physiology and Diabetes
NCT02550548
Completed
This project is designed to advance understanding of the incretin effect in health and disease. This system of gut-islet linkage is essential for normal glucose tolerance, impaired in T2DM, and amenable to therapeutic intervention. However, there are important gaps in understanding incretin function that limit application of this system; this project will address several of these. A secondary, but critical aspect of this research is focus on inter-individual variation in the physiology of the in... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/16/2023
Locations: Duke Center for Living, Durham, North Carolina
Conditions: Insulin Secretion
Register for Updates
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
NCT05161429
Recruiting
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/16/2023
Locations: HealthCore, Inc., Wilmington, Delaware +4 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
NCT01794143
Completed
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
04/13/2022
Locations: University of Alabama-Birmingham, Birmingham, Alabama +35 locations
Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Register for Updates
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
NCT02787551
Completed
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change. Secondary Objectives: To compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC to GLP-1 RA on top of metformin (with or without pioglitazone, with or without sodium-glucose co-transporter 2 \[SGLT2\] inhibitor) in participants with type 2 diabetes. To evaluate safety, efficacy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2022
Locations: Investigational Site Number 8400064, Birmingham, Alabama +123 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant
NCT03415139
Unknown
This clinical research studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation. Oral glucose tolerance tests (OGTT), hyperglycemic clamps, and immune assays will be used to define the mechanisms associated with abnormal glucose homeostasis following stem cell transplantation. Information from this clinical trial could be used to develop standardized screening procedures or to develop optimal treatment strate... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/10/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Diabetes Mellitus, Cancer
Register for Updates
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
NCT04133922
Withdrawn
GLP-1 increases skeletal and cardiac microvascular perfusion and improves insulin's microvascular responses in human subjects with T1DM, leading to improved metabolic insulin responses, endothelial function, and increased muscle oxygenation
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/07/2022
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Type 1 Diabetes, Insulin Sensitivity/Resistance
Register for Updates
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
NCT05220917
Unknown
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2022
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Cardiovascular Events, Type2 Diabetes, Renal Disease
Register for Updates
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
NCT02229227
Completed
This Phase IIIb, randomized, open-label, parallel group, active control, multicenter, treat to-target study of 26 weeks' treatment duration will evaluate the efficacy and safety of once-weekly albiglutide as replacement of prandial insulin in subjects with type 2 diabetes mellitus (T2DM) failing to achieve adequate glycemic control on their current basal bolus insulin regimen (with or without metformin). Approximately 794 subjects will be randomly assigned in a 1:1 ratio to 1 of 2 treatment grou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2020
Locations: GSK Investigational Site, Searcy, Arkansas +157 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
NCT02846233
Completed
In traditional step-up approach, the patients with poorly-controlled type 2 diabetes are instructed to take up to 4 insulin injections daily or multiple daily injections (MDI) as the most advanced therapy. However, a significant number of these patients continue to have poor diabetes control. The most common reason is the noncompliance with multiple injections and the patient's reluctance to accept insulin-induced weight gain. More recently, the algorithm in diabetes management has significantly... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
10/20/2020
Locations: UCSF Fresno, Fresno, California
Conditions: Type 2 Diabetes Mellitus
Register for Updates
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
NCT02793154
Terminated
The primary objective of this study is to compare the effect of albiglutide and exenatide on gastric myoelectrical activity (GMA), gastric emptying (GE) and nausea (as measured by visual analogue scale \[VAS\]) in subjects with type 2 diabetes mellitus (T2DM). The study is divided in two parts. Part A will characterize the GMA, GE and nausea response to exenatide and confirm exenatide as a positive control for Part B. Part B will compare the effects of albiglutide and exenatide on GMA, GE and na... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/08/2020
Locations: GSK Investigational Site, Louisville, Kentucky +1 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
NCT02802514
Terminated
The drug effects will be studied after a single dose of 50 milligram (mg) albiglutide and a single dose of 10 microgram exenatide, to gain insight into the central mechanisms of nausea associated with Glucagon-like peptide-1 receptor (GLP-1R) agonists. This study will explore the potential differences at the expected time of maximum concentration (Cmax) between a long-acting (albiglutide) and short-acting (exenatide) GLP-1R agonist in brain activation of healthy volunteers assessed by magnetic r... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/08/2020
Locations: GSK Investigational Site, Boston, Massachusetts
Conditions: Diabetes Mellitus
Register for Updates
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
NCT04034524
Unknown
This study will compare hemoglobin a1c (HbA1c) and cardiovascular (CV) outcomes among patients with type 2 diabetes newly initiating a GLP1-receptor agonist or basal insulin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2020
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates